Compare · COSM vs MCK
COSM vs MCK
Side-by-side comparison of Cosmos Health Inc. (COSM) and McKesson Corporation (MCK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COSM and MCK operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- MCK is the larger of the two at $105.52B, about 5105.2x COSM ($20.7M).
- Over the past year, COSM is down 98.7% and MCK is up 32.0% - MCK leads by 130.7 points.
- MCK has been more active in the news (8 items in the past 4 weeks vs 4 for COSM).
- MCK has more recent analyst coverage (25 ratings vs 0 for COSM).
- Company
- Cosmos Health Inc.
- McKesson Corporation
- Price
- $0.22+3.81%
- $896.78-0.93%
- Market cap
- $20.7M
- $105.52B
- 1M return
- +11.60%
- +0.83%
- 1Y return
- -98.70%
- +31.95%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 8
- Recent ratings
- 0
- 25
Cosmos Health Inc.
Cosmos Holdings Inc. operates as a vertically integrated pharmaceutical company. It offers proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications, health care, baby products, medical devices, and other products through its distribution channels and e-commerce market place. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece, and the United Kingdom; and warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. The company was formerly known as Prime Estates and Developments, Inc. and changed its name to Cosmos Holdings Inc. in November 2013. Cosmos Holdings Inc. was incorporated in 2009 and is based in Chicago, Illinois.
McKesson Corporation
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Latest COSM
- Cosmos Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway
- SEC Form 10-Q filed by Cosmos Health Inc.
- SEC Form NT 10-Q filed by Cosmos Health Inc.
- Chief Executive Officer Siokas Grigorios bought $70,000 worth of shares (349,825 units at $0.20), increasing direct ownership by 2% to 14,597,917 units (SEC Form 4)
- Chief Financial Officer Terzis Georgios was granted 328,407 shares, increasing direct ownership by 15% to 2,563,805 units (SEC Form 4)
- Chief Executive Officer Siokas Grigorios bought $140,000 worth of shares (766,284 units at $0.18), increasing direct ownership by 6% to 14,248,092 units (SEC Form 4)
- Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels
- SEC Form RW filed by Cosmos Health Inc.
- Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units
Latest MCK
- McKesson Signs Agreement to Acquire Precision Medicine Group, LLC
- RBC Capital Mkts initiated coverage on McKesson with a new price target
- SEC Form 4 filed by EVP and Chief Strategy Officer Srinivasan Ramesh (Nmn)
- Director Lerman Bradley E sold $268,590 worth of shares (301 units at $892.33), closing all direct ownership in the company (SEC Form 4)
- New insider Srinivasan Ramesh (Nmn) claimed ownership of 11,959 shares (SEC Form 3)
- SEC Form 10-Q filed by McKesson Corporation
- McKesson Reports Fiscal 2027 First Quarter Results and Raises Full Year Adjusted EPS Guidance
- McKesson Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- McKesson Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Hinton James H.